TSP-1-1223 A/G Polymorphism as a Potential Predictor of the Recurrence Risk of Bladder Cancer in a Chinese Population
Table 2
Genotype and allele frequencies of the TSP-1-1223 A/G polymorphism among the bladder cancer cases and controls.
Genotypes
Cases ()
Controls ()
Crude OR (95% CI)
Adjusted OR (95% CI)b
%
%
AA
287
47.1
294
43.9
1.00 (reference)
1.00 (reference)
AG
245
40.2
298
44.5
0.151
0.84 (0.66–1.07)
0.083
0.80 (0.62–1.03)
GG
77
12.6
78
11.6
0.951
1.01 (0.70–1.46)
0.603
1.11 (0.75–1.63)
AA
287
47.1
294
43.9
1.00 (reference)
1.00 (reference)
AG + GG
322
52.9
376
56.1
0.244
0.88 (0.70–1.10)
0.191
0.85 (0.67–1.08)
AG + AA
532
87.4
592
86.6
1.00 (reference)
1.00 (reference)
GG
77
12.6
78
13.4
0.583
1.10 (0.77–1.56)
0.330
1.20 (0.83–1.72)
A allele
819
67.2
886
66.1
G allele
399
32.8
454
33.9
0.548
CI: confidence interval; OR: odds ratio. Two-sided test for either genotype distributions or allele frequencies between the cases and controls.
bAdjusted for age, gender, smoking, drinking status, and family history of cancer in logistic regression model.
